SCHEMBL4645032

SCHEMBL4645032

COc1ccc2c(c1)C(=O)c1ccccc1-2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.58
MAPT P10636 5/20 0.55
TDP1 Q9NUW8 4/20 0.55
RAB9A P51151 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
NPC1 O15118 3/20 0.55
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 2/20 0.55
HPGD P15428 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
MAPK1 P28482 1/20 0.55
GAA P10253 1/20 0.55
ALOX12 P18054 1/20 0.55
PTPRC P08575 1/20 0.54
AR P10275 1/20 0.54
TP53 P04637 2/20 0.54
POLB P06746 2/20 0.54
MAP2K7 O14733 1/20 0.54
GMNN O75496 1/20 0.54
LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Methoxyanthraquinone SCHEMBL222927 0.98 PTPN1 (0.60) PTPN1MAPTTDP1RAB9ASMN1; SMN2
SCHEMBL23111380 0.96 PTPRC (0.59) PTPN1MAPTTDP1RAB9ASMN1; SMN2
SCHEMBL17439396 0.96 MAPT (0.55) PTPN1MAPTTDP1RAB9ASMN1; SMN2
SCHEMBL2997273 0.92 PTPN1 (0.54) PTPN1MAPTTDP1RAB9ASMN1; SMN2
SCHEMBL10885799 0.92 CA1 (0.53) PTPN1MAPTRAB9AALDH1A1HPGD
SCHEMBL2252533 0.92 CA1 (0.57) PTPN1MAPTRAB9AALDH1A1HPGD
SCHEMBL30629120 0.92 CA1 (0.57) PTPN1MAPTTDP1RAB9ASMN1; SMN2
SCHEMBL8076766 0.92 CA1 (0.57) PTPN1MAPTTDP1RAB9ASMN1; SMN2
SCHEMBL7451901 0.92 CA1 (0.57) PTPN1MAPTRAB9AALDH1A1HPGD
SCHEMBL2993382 0.88 CA1 (0.53) PTPN1MAPTRAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637600-B2 Photocurable composition, cured product of same, photofusible resin composition and adhesive set RESONAC CORPORATION (JP) 2026-05-26 US disclosed
US-20260132243-A1 THERMOSETTING COMPOSITION AND CURED PRODUCT THEREOF, PHOTOMELTABLE COMPOSITION, AND STRUCTURAL BODY PRODUCTION METHOD RESONAC CORP (JP) 2026-05-14 US disclosed
EP-4410859-B1 THERMOSETTING COMPOSITION AND CURED PRODUCT THEREOF, PHOTO-MELTABLE COMPOSITION, AND STRUCTURAL BODY PRODUCTION METHOD RESONAC CORP (JP) 2026-04-29 EP disclosed
CN-120153035-A Resin member, reel body, package, and resin material 株式会社力森诺科 2025-06-13 CN disclosed
CN-115698135-B Photocurable composition, cured product thereof, photo-fusible resin composition, and adhesive kit 株式会社力森诺科 2024-12-17 CN disclosed
CN-119096330-A Method for manufacturing semiconductor device 株式会社力森诺科 2024-12-06 CN disclosed
WO-2024204615-A1 METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE 株式会社レゾナック 2024-10-03 WO disclosed
EP-4141079-B1 PHOTOCURABLE COMPOSITION, CURED PRODUCT OF SAME, PHOTOFUSIBLE RESIN COMPOSITION AND ADHESIVE SET RESONAC CORP (JP) 2024-09-25 EP disclosed
EP-4410859-A1 THERMOSETTING COMPOSITION AND CURED PRODUCT THEREOF, PHOTO-MELTABLE COMPOSITION, AND STRUCTURAL BODY PRODUCTION METHOD Resonac Corporation (JP) 2024-08-07 EP disclosed
CN-118251448-A Thermosetting composition, cured product thereof, photo-fusible composition, and method for producing structure 株式会社力森诺科 2024-06-25 CN disclosed
EP-1591098-A1 Cationically curable composition for dental use TOKUYAMA CORPORATION (JP) 2005-11-02 EP disclosed
US-20040186195-A1 Photopolymerization initiator and photopolymerizable composition TOKUYAMA CORPORATION (JP) 2004-09-23 US disclosed
EP-1431315-A2 Photopolymerization initiator and photopolymerizable composition Tokuyama Corporation (JP) 2004-06-23 EP disclosed
US-6162824-A NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS ALLELIX NEUROSCIENCE INC. 2000-12-19 US disclosed
US-5736578-A TREATMENT OF SLEEP DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-04-07 US disclosed
EP-0747345-A2 Ethylamido fluorenes and improved method of making same BRISTOL-MYERS SQUIBB COMPANY (US) 1996-12-11 EP disclosed
EP-0531443-A4 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN 1993-04-21 EP disclosed
EP-0531443-A1 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN NOVA PHARMACEUTICAL CORPORATION (US) 1993-03-17 EP disclosed
US-5079260-A Side effect reduction; fluorene derivatives NOVA PHARMACEUTICAL CORPORATION (US) 1992-01-07 US disclosed
WO-1991018596-A1 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN WEITZBERG MOSHE (US) 1991-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637600-B2 Photocurable composition, cured product of same, photofusible resin composition and adhesive set ESD, CDH1, ASH2L PTPN1 4789/4885MAPT 2260/4885TDP1 2103/4885
US-20260132243-A1 THERMOSETTING COMPOSITION AND CURED PRODUCT THEREOF, PHOTOMELTABLE COMPOSITION, AND STRUCTURAL BODY PRODUCTION METHOD RER1, OXTR, MAP1LC3A PTPN1 3190/4885MAPT 235/4885TDP1 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.